The company intends to use the funds to support the further advancement of its precision data analytics and multi-platform approach to explore ESK-001's potential application in other autoimmune indications, as well as A-005, a TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases, and its earlier-stage internal pipeline programs.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
San Francisco, CA 94105
USA

Phone

Undisclosed

Website

www.alumis.co

Email Address

[email protected]

Overview

Alumis (formerly Esker Therapeutics) is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Our experienced leadership team brings a proven track record in precision drug development of groundbreaking therapies.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

June Lee

Chief Information Officer

David Zhang

VP - Bus. Development

Mark Bradley

Browse more venture capital transactions:

Prev: 3/7/2024: Hari Mari venture capital transaction
Next: 3/7/2024: BrainCheck venture capital transaction

Share this article

About Database of VC Transactions

We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary